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Introduction
The diffusion and frequency of screening may confound
demographic comparisons of incidence rates by age,
race, ethnicity, socioeconomic status, geographic resi-
dence, and temporal trends. Prostate cancer encompass-
es a biologic spectrum ranging from the commonly
prevalent, latent, microscopic, pre-invasive, or minimal-
ly invasive form of the disease, which is not apparent
clinically, to the substantially diminished fraction, the
‘tip of the iceberg’, that is clinically manifested as
invasive and potentially fatal prostate cancer [1]. The
accelerated increases in prostate cancer incidence rates
in the United States during the late 1980s and early
1990s have been attributed mainly to increased utiliza-
tion of prostate-specific antigen (PSA)-based screening
and the urologic practice of random sextant biopsies
based on a PSA threshold in addition to biopsies in
suspect areas of digital rectal examination and ultra-
sound abnormalities [2–5]. Incidence and mortality have
decreased since the early 1990s [5]. The introduction of
an innovative cancer screening method into the popu-
lation is associated with enhanced lead-time in diagnosis
and expansion of the prevalent pool of diagnosed cases.
Alterations in incidence trends may be artifactual and
transient, unless there are concurrent factors that are
affecting risk in the target population. A challenging
aspect of research will be to address whether there are
common or contrasting causal factors in the pathogen-
esis of incipient, latent prostate cancer revealed through
screening when compared with clinically apparent dis-
ease diagnosed in the absence of screening.
Spectrum of prostatic neoplasia
Autopsy studies in United States men over the age of 50
have demonstrated that the prevalence of undetected
micro-invasive prostate carcinoma was about 30%. For
a 50-year old man, the remaining average lifetime risk of
developing clinically apparent prostate cancer has been
projected to be 9.5%, and of dying of prostate cancer,
2.9%. Autopsy studies conducted in different countries
or in different racial groups, at varying risks of
symptomatic or fatal prostate cancer, have described a
similar prevalence of clinically occult cancers in older
men [6, 7].
Initially, there was concern that the majority of
prostate cancers detected by PSA screening would be
non-progressing, or tumors that would, in most instanc-
es, not require aggressive treatment. Assessment of the
potential clinical significance of prostate carcinomas
detected by serum PSA elevation has been based on the
Gleason’s grade, pathologic stage, and tumor volume.
Clinical and pathological studies have estimated that
more than 50% of the carcinomas detected by PSA are
clinically significant. For example, the pathologic fea-
tures of 100 prostate cancer patients who were enrolled
in the Washington University PSA screening program
revealed a median tumor volume of 1.0 cm3, a median
Gleason score of six, and a confinement of only 61% of
tumors to the prostate gland. The clinical studies are
compatible with SEER trends after 1985 that have
described increased incidence rates for both localized
and regional cancers of intermediate histologic grade [2,
8].
The search for the precursor of prostatic cancer has
focused on the spectrum of histopathologic changes
referred to as prostatic intraepithelial neoplasia (PIN).
PIN is characterized by atypical or dysplastic cellular
proliferation in ducts and acini occurring most com-
monly in the peripheral zone of the prostate (about
85%), in comparison with the central (<15%) and
transition (about 1%) zones. High-grade PIN, or
moderate to severe dysplasia co-exists with prostate
cancer in more than 80% of cases, and is significantly
predictive of prostate cancer on subsequent follow-up
and repeated biopsy. High-grade PIN on biopsy signals
a 30–50% cumulative incidence of prostate cancer on
subsequent biopsies. Thus, patients with multi-focal
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high-grade PIN are a strategic subgroup in the popu-
lation suitable for studies of screening methods and
chemoprevention trials [9, 10].
The morphologic continuum that proceeds from a
subset of foci of PIN to invasive adenocarcinoma is
characterized by progressive disruption of the basal cell
layer, increasing nuclear and nucleolar alterations,
increasing rates of cell proliferation, aberrant apoptosis,
variation in DNA content, aneuploid nuclei, increasing
microvessel density or neovascularity, and increasing
genomic instability associated with cumulative chrom-
osomal and allelic losses or gains. Dysregulation of
genes in the pathogenesis of invasive prostate cancer
include the overexpression of oncogenes (e.g., Ha-ras)
and loss of expression of tumor suppressor genes (e.g.
p53, Rb, chromosome 8p) associated with critical cell
functions such as proliferation, differentiation, cell
adhesion, DNA repair, and angiogenesis. Fluorescence
in situ and comparative genomic hybridization studies
have revealed similar chromosomal anomalies in PIN
and invasive prostate cancer, although at a greater
frequency in invasive tumors and in a subset of PIN
lesions. Chromosomal aberrations in PIN lesions in-
clude losses on 8p and 13q and gains on 8q. In the
morphogenesis of metastatic prostate carcinoma, losses
on chromosomes 2, 5, 18 and X, and gains on 7, 9, 12q
and 15q have been reported. The validation of molec-
ular genetic events in the subset of PIN lesions that are
predictive of tumor progression may serve to guide
treatment planning and future molecular epidemiologic
studies. Immunohistochemical expression studies and
serum concentration levels of PSA are not yet elevated
in patients with PIN in the absence of invasive prostate
cancer [11, 12].
Prostate cancer mortality in African Americans
The average annual age-standardized prostate cancer
mortality rate during 1990–1997 in US blacks was more
than twice (2.32) of that in whites. The more than
twofold higher prostate cancer mortality experienced by
US blacks, when compared with US whites, has been
attributed to a relatively higher frequency of poorly
differentiated invasive tumors of larger volume, a more
advanced stage at diagnosis that is predictive of a higher
recurrence rate, and a higher prevalence of co-morbid
diseases that may impact the outcome because of deaths
due to other causes [2, 13, 14]. In an analysis of
knowledge, attitudes, and screening practices among
older men (50–74 years of age) regarding prostate
cancer, which was based on a random digit-dialed
telephone interview survey conducted in New York
State, black men were 0.3 times as likely as non-
Hispanic white men to report ever having had a PSA test
[15]. Socioeconomic impediments and the omission of
active interventions or recommendations for screening
by physicians are correlated with lower utilization of
early detection methods, but even after controlling for
age, stage and tumor grade, US blacks at the time of
diagnosis of prostate cancer are reported to have higher
mean serum PSA levels and a subsequently higher risk
of prostate cancer-specific mortality [16]. Based on a
study of 584 decedent prostate cancer cases treated at
the Kaiser Permanente Medical Care Program, approx-
imately 54% (95% CI 50–58%) of deaths were certified
as due to prostate cancer. When comparing prostate
cancer subjects who were listed as dying of prostate
cancer with those prostate cancer subjects who were
certified as dying of other causes, decedents who were
black were more likely to have died of prostate cancer,
after controlling for age, stage, comorbidity (e.g.,
cardiovascular disease, diabetes) at diagnosis of prostate
cancer, initial treatment, and time to death (OR¼ 1.59,
95% CI, 1.01–2.53) [17]. Incidence in Los Angeles
County was not related to socioeconomic status prior to
the PSA screening era, but now, is directly related to
SES [18]. Recent data from the population-based
prostate cancer outcomes study indicate that prostate
cancer is more advanced at diagnosis among African
American men even after adjusting for a broad set of
socioeconomic and clinical factors [19]. These issues
require further evaluation as they contribute only in part
to the racial disparities.
Prostate cancer screening and epidemiologic inferences
As reported in SEER and Olmsted County, concurrently
with the diffusion of PSA testing in medical practice,
there has been enhancement of the clinical and patho-
logical prognostic features of prostate cancer [2, 20]. The
incidence rate of distant or metastatic prostate cancer at
diagnosis decreased from 14.9 per 100,000 in 1985 to 6.6
per 100,000 in 1995, whereas there was a substantial
relative and absolute increase in the incidence of
localized, organ-confined prostate cancer, and of re-
gional disease, namely disease that has extended through
the prostatic ‘capsule’ [2]. Such changes are consistent
with screening but fail to indicate whether it is effective
as a public health strategy, which requires a mortality
benefit [21].
The extent of disease at diagnosis is correlated with
histologic grade of differentiation. Histologic grade,
based on Gleason’s scoring, may be classified as well-
differentiated (scores of 2–4), moderately differentiated
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(scores of 5–7), and poorly differentiated (scores of 8–
10). These histologic patterns are categorized at low
microscopic magnification according to the extent of
glandular differentiation and the pattern of growth of
the tumor within the prostatic stroma. Prostate cancers
may contain dominant and secondary histological pat-
terns in relationship to increasing tumor volume and
multi-centric clonal foci of pathogenesis. Gleason as-
signed a primary grade score (1–5) to the dominant
pattern, and a secondary pattern grade score (1–5), and
then both scores were summed. More than 80% of
prostate cancer cases with well-differentiated tumors
(Gleason 2–4) are staged as localized disease. In
contrast, only 42% of men with poorly differentiated
cancers (Gleason 8–10) are staged as localized. The
increase in prostate cancer incidence in the United States
reported after 1985 consisted primarily of an increase in
Gleason 5–7 moderately differentiated cancers. With
respect to prostate cancer cases clinically staged as
localized, both histologic grade and the concentration
level of serum PSA at diagnosis are predictive of
survival [22–25].
In the absence of uniform national or regional
guidelines for prostate cancer screening practices, one
must ask the question, are there distinguishing charac-
teristics among men who were screened from those who
were never screened? Selection bias would impact
medical and epidemiologic studies when the character-
istics of participating subjects would differ from the
population that is the target for inferences drawn from
the study data. To overcome such bias, community-
based studies may offer new insights. One such study, a
community-based epidemiologic study of prostate can-
cer and benign prostatic hyperplasia (BPH) in US black
men of 40–79 years of age, is being conducted in Flint,
Michigan. This study has investigated potential selection
bias among participants when determining the age-
specific distribution of serum concentration levels of
prostate-specific antigen. A probability sample of 819
African American men completed an in-home epidem-
iologic interview, and among those without a history of
prostate cancer or prostate surgery, blood was drawn
for PSA testing. In addition, the control subjects
without prostate cancer were examined clinically by a
urologist for obstructive urinary tract symptoms, rate of
urine flow, digital rectal examination and transrectal
ultrasonography of the prostate.
While previous studies conducted among various
racial and ethnic groups have emphasized that social,
cultural, and economic factors affect cancer screening
and preventive attitudes and practices, the Michigan
study controlled for economic barriers, but underscored
other important differences among participants from a
high-risk minority group. Namely, younger men with
current lower urinary tract symptoms, and a family
history of prostate cancer were more likely to participate
in a protocol of PSA testing and clinical urological
examination. However, neither family history nor the
number of obstructive or irritative lower urinary tract
symptoms was a significant predictor of log PSA values
in the black men [26, 27].
The concern for potential confounding and misclas-
sification bias would arise when comparing screen-
detected cases with unscreened controls. Confounding
would occur when characteristics (positively or inverse-
ly) associated with screening are also predictive of stage-
specific prostate cancer. For example, family history of
prostate cancer appears to be positively correlated with
the utilization of screening tests for prostate cancer, and
prostate cancer screening ‘exposures’ may confound
genetic anticipation studies of successive generations in
family pedigrees. In genetic anticipation, age of onset (or
diagnosis) of disease occurs earlier with greater severity
over successive generations, and has been attributed to
the variable number of tandem repeats (e.g., trinucleo-
tide repeats) in an inherited susceptibility locus [28].
With the introduction of an innovative screening
method, the enhanced sensitivity for early detection
would tend to shift the stage distribution of prostate
cancer cases in a population. Detection by screening
would favor cancer cases that are less aggressive or with
relatively longer average tumor doubling time when
compared with clinically diagnosed symptomatic cases
because of ‘length-bias’, and this phenomenon would be
reflected in prolonged diagnostic ‘lead-time’. Converse-
ly, ‘interval’ cancers, diagnosed after prior negative
screening examinations, may exhibit aggressive behavior
and metastatic potential. Early molecular and morpho-
logic events of carcinogenesis may be associated with a
subset of environmental risk factors that are distin-
guished from risk factors impacting extracapsular ex-
tension and ultimately fatal prostate cancer.
For example, epidemiologic studies of cigarette smok-
ing and the risk of metastatic or fatal prostate cancer has
considered screening behavior in smokers and non-
smokers. Cohort studies have reported modest associ-
ations, namely rate ratios <2.0 in current smokers or
smokers who stopped less than 10 years prior to
diagnosis [29–31]. In the study of health professionals
by Giovannucci et al., the higher rate of fatal prostate
cancer among smokers was inferred after controlling for
other lifestyle risk factors, smoking-related co-morbid-
ities, and frequency of screening examinations [32].
There was no indication of any delay in diagnosis and
treatment as a result of lower frequency of prior
screening exams at baseline among smokers compared
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with never smokers. Assuming that uncontrolled resid-
ual confounding does not account for the association,
pathogenic mechanisms have been hypothesized for
systemic and intraprostatic effects of tobacco smoke.
Namely, the putative mechanism may include effects on
estrogen and androgen metabolism, perturbations in
immune function, or gene–tobacco interactions. Most
intriguing is the effect of cigarette smoking on increased
serum levels of testosterone, dihydrotestosterone, and
androgenic hormones formed by the adrenal gland [33,
34].
Future directions in research
Randomized screening trials are in progress in the
United States and Europe to address the relationship
between PSA and digital rectal examination screening
strategies and prostate cancer mortality [35]. The results
of these trials may ultimately influence global policies
and practices, incidence, and mortality trends. We may
anticipate, however, that access and utilization in a
geographic area will continue to be uneven and corre-
lated with sociocultural, economic and lifestyle risk
factors, family history, urologic symptoms, and other
comorbidity characteristics. Lack of standardization of
assay methods and clinical examination procedures,
threshold criteria for prostatic biopsy, age at initiation
of screening, and recommended screening intervals, will
confound the interpretation of demographic trends and
impact the heterogeneous nature of diagnosed cases.
Either by design or analysis, discrepancies between
study and control subjects in prior baseline or follow-up
screening exposures should be considered as they may
affect the magnitude or direction of putative causal
associations. Stratification of cases by clinical staging,
grade of differentiation, molecular tumor prognostic
markers, and whether the cases were detected by
screening will serve to sharpen the focus on the
independent or interactive relationships of environmen-
tal risk factors, endogenous hormones, and peptide
growth factors, as well as genetic susceptibility poly-
morphisms.
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